Gilead Sciences' Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate ...

And Simon Kohl, founder and CEO of Latent Labs, knows this intimately. In a new episode of the pharmaphorum podcast, Kohl ...

The company's BCMAxCD3 bispecific antibody Lynozyfic (linvoseltamab) got its first FDA approval as a fifth-line or later ...

In line with its deregulatory stance under new Commissioner Marty Makary, the US regulator has launched TEMPO – ...

Social determinants of health (SDOH) encompass a wide range of non-medical factors that influence health and well-being.

At this year's ASH congress, the results of the phase 1b/2 DURGA-1 of AZD0120 – a dual BCMA and CD19-directed CAR-T therapy – ...

The CDC's Advisory Committee on Immunization Practices (ACIP) has voted by 8 to 3 to remove the recommendation that all infants aged under two months receive a hepatitis B virus (HBV) vaccine, ...

At Frontiers Health 2025, Drew McCormick, Head of Data and Analytics at EVERSANA, emphasised a critical truth: data strategy ...

The EMBOLD study of relutrigine (also known as PRAX-562) was testing the oral drug in patients with SCN2A and SCN8A ...

Protego Biopharma is poised to start pivotal trials of its amyloid light-chain (AL) amyloidosis drug candidate, thanks to a ...

A CDMO plays a crucial role in the pharmaceutical and biotechnology industries by providing comprehensive drug development ...

CD19-targeted therapy Breyanzi (lisocabtagene maraleucel) can now be used to treat adults with MZL – a rare and form of ...